Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cbd GT4 is a topical formulation that combines cannabidiol (CBD) with the proprietary Gefion GT4 transdermal delivery technology. This system uses an emulsion containing novel penetrating agents, basement membrane disruptors, and vasodilators to overcome both hydrophilic and lipophilic barriers in the skin. The mechanism enables cannabinoids like CBD (and THC in some studies) to be transported deep into the dermis and then into systemic circulation via dilation of capillary beds at the application site. This approach is designed to achieve steady-state cannabinoid plasma levels for chronic conditions while minimizing psychoactive effects, as demonstrated by clinical studies showing no intoxication or significant adverse events in healthy volunteers. The product has been investigated for its potential benefits in treating chronic conditions requiring sustained cannabinoid delivery, especially where oral or patch-based routes are suboptimal[2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cbd GT4.